Claims
- 1. A method of treating depression, an obsessive compulsive disorder or anxiety in a human in need thereof which comprises administering an effective amount of melatonin receptors (MT-3) agonists: 5-methoxy-carbonylamino-N-acetyltryptamine (5-MCA-NAT) or analogs thereof, the analogs having the following formula I:
- 2. The method of claim 1, wherein said MT-3 agonists are administered by the oral route.
- 3. The method of claim 1, wherein said MT-3 agonists are administered together with an acceptable carrier therefor.
- 4. The method of claim 1, wherein said MT-3 agonists are administered in the form of an orally ingestible capsule or tablet.
- 5. The method of claim 1, wherein said MT-3 agonists are administered in combination with a Ca++ antagonist.
- 6. The method of claim 6, wherein the Ca++ antagonist is nifedipine.
- 7. A pharmaceutical composition comprising an MT-3 agonist of the following formula I:
- 8. The pharmaceutical composition of claim 7, further comprising a Ca++ antagonist.
- 9. The pharmaceutical composition of claim 8, wherein the Ca++ antagonist is nifedipine.
- 10. The method of claim 1, further comprising administration of a serotonin reuptake inhibitor.
- 11. The method of claim 1, further comprising the administration of a tricyclic antidepressant.
- 12. The method of claim 11, wherein the tricyclic antidepressant is bupropion.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 09/559,609 filed on Apr. 27, 2000, the content of which is relied upon and incorporated by reference in its entirety, and benefit of priority under 35 USC §120 in hereby claimed, which claims the benefit of U.S. Provisional Application No. 60/134,573 filed May 17, 1999.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09559609 |
Apr 2000 |
US |
Child |
09834041 |
Apr 2001 |
US |